Premium
MiR‐29a, targeting caveolin 2 expression, is responsible for limitation of pancreatic cancer metastasis in patients with normal level of serum CA125
Author(s) -
Liang Chen,
Shi Si,
Meng Qingcai,
Liang Dingkong,
Hua Jie,
Qin Yi,
Zhang Bo,
Xu Jin,
Ni Quanxing,
Yu Xianjun
Publication year - 2018
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/ijc.31654
Subject(s) - pancreatic cancer , metastasis , cancer research , microrna , downregulation and upregulation , cancer , biology , adenocarcinoma , medicine , oncology , gene , biochemistry
Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive gastrointestinal tumors, with an overall 5‐year survival rate less than 8%. The dismal prognosis is mainly due to aggressive potential for metastasis. Hence, there is an urgent need for a better understanding of the molecular mechanisms underlying pancreatic cancer invasion and metastasis to improve the unfavorable overall survival (OS) of PDAC patients. In this study, we identified microRNA‐29a (miR‐29a) as an important tumor suppressor, which was downregulated in PDAC tissues. Moreover, miR‐29a counteracted MUC16‐mediated migration and invasion. In the pancreatic cancer cells, MUC16 upregulated c‐Myc expression, which enhanced c‐Myc binding to E‐box in the miR‐29a promoter and inhibited miR‐29a transcription. Thus, miR‐29a was negatively correlated with both MUC16 expression and serum CA125 levels. Furthermore, caveolin 2 (CAV2) was demonstrated to be the target of miR‐29a by bioinformatics and luciferase reporter assays, and high CAV2 expression was responsible for a poor prognosis, especially in the subgroup with normal CA125 levels. Thus, the present study explains why high levels of serum CA125 are correlated with PDAC metastasis, highlighting the predictive value of this marker in PDAC patients.